## **OncoTargets and Therapy**

Open Access Full Text Article

#### CORRIGENDUM

# Partial Stereotactic Ablative Boost Radiotherapy in Bulky Non-Small Cell Lung Cancer: A Retrospective Study [Corrigendum]

Bai Y, Gao XS, Qin SB, et al. *Onco Targets Ther.* 2018;11:2571–2579.

Recently the authors found two main errata in the text that need to be corrected.

On page 2571, Abstract, Results section, "Two-year overall survival was 55.6%. Two-year local control rate was 85.7%" should read "One-year overall survival was 64.9%. One-year local control rate was 100%".

On page 2574, Response and survival outcomes section, 3rd and 4th sentences, "One-year over-all survival was 88.2%. Two-year overall survival was 55.6% (Figure 2A)." should read "One-year over-all survival was 64.9%. Two-year overall survival was 44.5% (Figure 2A)."

On page 2574, Response and survival outcomes section, 10th sentence, "Two-year local control rate was 85.7%. (Figure 2B)." should read "Two-year local control rate was 57.1%. (Figure 2B)."

On page 2575, Figure 2 legend, "(A) Kaplan–Meier plots of overall survival for all patients. One-year overall survival was 88.2%. Two-year overall survival was 55.6%. (B) Kaplan–Meier plots of local control for all patients. One-year local control rate was 100%. Two-year local control rate was 85.7%. (C) Patients with B90≥65% (n=19) achieved a higher local control rate than those with B90<65% (n=11) (median survival=15.2 months vs 3.5 months, CI=6.8–23.6 and 2.2–4.9 months, respectively; P=0.010). (D) Patients with B80≥90% (n=20) achieved a higher local control rate than those with

B80<90% (n=10) (median survival=14.9 months vs 3.5 months, CI=3.4–26.3 and 1.8–5.2 months, respectively; P=0.045)." should read "(A) Kaplan–Meier plots of overall survival for all patients. One-year overall survival was 64.9%. Two-year overall survival was 44.5%. (B) Kaplan–Meier plots of local control for all patients. One-year local control rate was 100%. Two-year local control rate was 57.1%. (C) Patients with B90≥65% (n=19) achieved a higher local control rate than those with B90<65% (n=11) (median survival=15.2 months vs 3.5 months, CI=6.8–23.6 and 2.2–4.9 months, respectively; P=0.010). (D) Patients with B80≥90% (n=20) achieved a higher local control rate than those with B80<90% (n=10) (median survival=14.9 months vs 3.5 months, CI=3.4–26.3 and 1.8–5.2 months, respectively; P=0.045)."

On page 2576, Discussion section, last sentence "Therefore, daily SABR was applied in our article and the 2-year local control rate was as high as 85.7%, even stage IV NSCLC were 40%." should read "Therefore, daily SABR was applied in our article and the 1-year local control rate was as high as 100%, even stage IV NSCLC were 40%."

Despite the correction in the text list as above, the Figures of Kaplan–Meier plots of overall survival and local control are correct, and the error doesn't the change the overall findings reported in the paper. We can still conclude that "This retrospective study suggests that P-SABR is feasible and well tolerated in bulky NSCLC. Local control rate is encouraging, especially for the B90≥65% group, which may due to the ability of P-SABR to optimize BED with equivalent toxicity". The authors apologize for this error.

### **OncoTargets and Therapy**

## **Dove**press

1185

#### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.



#### OncoTargets and Therapy 2020:13 1185

© 2020 Bai et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial uses of this work, please see paragraphs 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php).